The third generation tyrosine kinase inhibitor aciminib

Aximini, this new type of BCR-ABL targeted therapy, marks the entry into a new era of the third generation in the field of tyrosine kinase inhibitors (TKI). It is designed for patients with chronic myeloid leukemia (CML), especially those who have developed resistance to early-stage TKI drugs or have genetic mutations.

Looking back on the development history of TKI, the emergence of the first-generation drug imatinib has greatly improved the therapeutic efficacy of CML patients. However, drug resistance and intolerance issues still plague some patients. To this end, second-generation TKIs such as nilotinib and dasatinib have emerged, but they are still insufficient to deal with specific mutations, especially the T315I mutation. Against this background, the third generation of Aceminib was developed, specifically developed to address these drug-resistant mutations.

Aximini's unique mechanism is that it acts on the "myristoyl" pocket of the ABL1 protein. This binding site is completely different from previous TKI. By virtue of this mechanism, Aceminib can effectively inhibit the activity of BCR-ABL protein, including those mutation types that are resistant to other TKIs, especially the troublesome T315I mutation. This makes aximini show extraordinary potential in the treatment of CML patients who are resistant to existing TKIs.

Currently, Asiminib has been approved in many countries for the treatment of CML patients who have failed two or more TKI treatments. Side effects are relatively mild, mainly including fatigue, nausea, and rash, but are generally well tolerated by patients.

To sum up, the research and development and clinical application of aceminib are undoubtedly CMLA major advancement in treatment. It opens up new treatment avenues and brings new hope to patients who have failed or developed drug resistance after treatment with previous generations of TKIs.